CTLA4[Biotinylated]:B7-2 Inhibitor Screening Assay Kit

Catalog #: 72024
Size: 96 reactions
B7-2 (CD86) signaling through CTLA4(CD152) has been shown to inhibit T cell activation. This co-inhibitory pathway can be overactive in many tumors, enabling cancers to escape the host’s immune system. CTLA4-blocking antibodies, including Ipilimumab (Yervoy) and Tremelimumab, have shown clinical efficacy in treating cancer.

The CTLA4[Biotinylated]:B7-2 Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of CTLA4:B7-2 interaction. The key to this kit is the high sensitivity of detection of biotin-labeled CTLA4 by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, B7-2 is coated on a 96-well plate. Next, CTLA4-biotin is incubated with B7-2 on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can then be measured using a chemiluminescence reader.

T-lymphocyte activation antigen CD86, B7.2, FUN-1, B70, BU63, CD86, Cytotoxic T-lymphocyte-associated protein 4, CD152, B72
Supplied As:
This kit comes in a convenient 96- well format, with biotin-labeled CTLA4 (CD152), purified B7-2 (CD86), streptavidin-labeled HRP, and assay buffer for 100 binding reactions

Instructions for use:
See assay kit data sheet for detailed protocol
Storage / Stability:
Stable at least 6 months from date of receipt, when stored as directed. Kit components require different storage conditions. Be sure to store each component at the proper temperature upon arrival
This kit is useful for screening for inhibitors of CTLA4 binding to B7-2.
1. Ohtani, H., et al., Lab Invest. 1997; 77(3): 231-241.
2. Rovert, C., et al., N. Engl. J. Med. 2011; 364: 2517-25262.
Avoid freeze/thaw cycles.
Scientific Category:
Immunotherapy/Cell Surface Receptor
Product Type:
Assay Kit
Data shown is lot-specific. Contact us for specific information on other lots.

Quality Assurance

Product Datasheets